Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study
- 512 Downloads
High-dose melphalan and autologous stem cell transplantation (ASCT) are associated with high symptom burden. This study aimed to explore multiple myeloma (MM) patients’ experience of symptom frequency, intensity, and distress during therapy.
This descriptive longitudinal study enrolled 29 MM patients who completed the 43-item PROVIVO questionnaire, measuring symptom experience across the dimensions of frequency, intensity, and distress at four assessment points: hospital admission (T0), leucocyte nadir (T1), discharge (T2), and 30 days post discharge (T3). Symptom assessment covered five categories: (1) physical, (2) emotional, (3) cognitive, (4) male/female urogenital symptoms, and (5) follow-up care planning (e.g., financial problems). Results were displayed as heat maps and bubble graphs for each patient, differences between T0 and T4 individually assessed, and intensity (IMS) and mean distress scores (DMS) calculated on a scale from 0 to 4.
The most frequent, intense, and distressing physical symptoms were fatigue, diarrhea, and decreased appetite. As expected, peak symptom intensity (decreased appetite 2.79) and distress (diarrhea 2.11) were reported during high-dose melphalan and the leucocyte nadir (T1). Thereafter, most symptoms’ intensity and distress improved. Items on urogenital symptoms remained predominantly unanswered or patients were sexually inactive.
PROVIVO enabled exploration of various dimensions of MM patients’ symptom experiences, which differed substantially before and after ASCT. Our results suggest that high-dose melphalan, ASCT, and other intensive novel agent therapies warrant targeted symptom management programs that include focused patient support.
KeywordsMultiple myeloma High-dose melphalan Autologous stem cell transplantation Symptom experience Symptom management
We wish to express our gratitude to Gila Sellam of the Institute of Nursing Science, Basel, for her review and useful discussions concerning this paper. We are also deeply indebted to Prof. Dr. Anca Grosu (Radiation Oncology, UKF), Prof. Dr. Georg Herget, Prof. Dr. Norbert Südkamp (Orthopedic and Traumatology, UKF), and the entire interdisciplinary MM tumor board for their intensive support and fruitful interaction for the sake of our MM patients. We are also grateful to Dr. Anne Rebafka, Freiburg, to Chris Shultis, Basel, for proofreading the manuscript, to Prof. Dr. Hermann Einsele and Prof. Dr. Stefan Knop (University of Würzburg), and to Prof. Dr. Hartmut Goldschmidt (University of Heidelberg) for deeply supportive and insightful recommendations at national and international meetings regarding our results.
This work is supported by the Deutsche Krebshilfe (grants 1095969 and 111424 [to ME]).
Compliance with ethical standards
The analysis followed the guidelines of the Declaration of Helsinki principles and good clinical practice. All the patients gave written informed consent for institutionally initiated research studies and analyses of clinical outcome studies conforming to institutional review board guidelines. The study proposal was approved by the ethics committee of the University Hospital Freiburg, Germany (EV 339/12).
Conflict of interest
The authors declare that they have no conflicts of interest.
- 2.Deutsches Register für Stammzelltransplantationen. Jahresbericht 2011. 2011 14.11.2011]; Available from: http://www.drst.de/download/jb2010.pdf
- 19.Williams LA et al (2014) Symptom burden of busulfan + melphalan versus melphalan alone for multiple myeloma. Blood 124(21):1277–1277Google Scholar
- 24.U.S. Department of Health and Human Services, National Institutes of Health, and N.C. Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2010 04.12.2015]; Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
- 25.Berger D et al (2009) Das Blaue Buch: Chemotherapie-Manual Hämatologie und Onkologie, 3rd edn. Springer, BerlinGoogle Scholar
- 28.Knop S et al (2014) Response to lenalidomide, doxorubicin and dexamethasone (RAD) in newly diagnosed multiple myeloma is independent of cytogenetic risk and retained after double stem cell transplant. Blood 124(21):177–177Google Scholar
- 30.Engelhardt M et al (2016) Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? HaematologicaGoogle Scholar
- 41.Terpos, E., et al., European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica, 2015. 100(10): p. 1254–1266Google Scholar